Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Feb;31(1):1-5.
doi: 10.5114/pdia.2014.40553. Epub 2014 Feb 25.

Loss of asthma control after cessation of omalizumab treatment: real life data

Izabela Kupryś-Lipińska  1 , Piotr Kuna  1
Affiliations

Loss of asthma control after cessation of omalizumab treatment: real life data

Izabela Kupryś-Lipińska et al. Postepy Dermatol Alergol. 2014 Feb.

Abstract

Introduction: Many clinical and observational studies have demonstrated effectiveness of omalizumab (OMA) in the treatment of severe asthma, but the optimal duration of the therapy remains unknown.

Aim: The article presents the authors' clinical experience on OMA cessation in routine practice.

Material and methods: Due to new reimbursement criteria, OMA therapy has been interrupted in 11 subjects (6 women/5 men). The mean age of patients was 50.73 ±14.16 years, the mean time of severe asthma duration was 13.54 ±6.05 years. All of them had an excellent/good response to OMA. The duration of OMA therapy was 67.73 ±11.64 months.

Results: Nine out of 11 patients had severe asthma exacerbation within the first 5 months after the OMA withdrawal. The mean time to the first severe exacerbation was 7.56 ±2.67 weeks. Between the time of OMA cessation and the time of reassessment, the mean score of Asthma Control Questionnaire increased from 2.58 ±0.71 to 3.63 ±1.26 points and the mean score of Asthma Quality of Life Questionnaire decreased from 4.3 ±1.91 to 3.18 ±1.17 points. The mean oral corticosteroids (OCS) dose increased from 4.61 ±3.0 mg/day to 33.33 ±13.12 mg/day. The number of exacerbations within the last 12 months increased from 1.6 ±0.67 to 5.2 ±1.4, and the number of hospitalizations or emergency room (ER) attendence increased from 0.11 ±0.31 to 1.56 ±1.26.

Conclusions: These data indicate that the withdrawal of OMA therapy after the successful long-term therapy may cause severe asthma exacerbations. Therefore, the decision regarding cessation of OMA treatment should be undertaken individually after careful weighing benefits and risks, especially in patients with a long history of severe asthma, treated with high doses of OCS before OMA introduction, near-fatal asthma events and/or aggravation of asthma during previous episodes of interruptions in OMA treatment.

Keywords: asthma deterioration; discontinuation; exacerbations; omalizumab; severe asthma.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Changes in ACQ, AQLQ, daily dose of OCS and number of severe exacerbations per year during the discontinuation of omalizumab – data for 9 patients
See this image and copyright information in PMC

References

    1. Kupryś I, Kuna P. Epidemics of allergic diseases: a new health problem in the modern world. Pol Merkur Lekarski. 2003;14:453–5. - PubMed
    1. Kupryś-Lipińska I, Kuna P. Praktyczne wskazówki dotyczące terapii omalizumabem [Polish] Terapia. 2011;255:42–8.
    1. Marandi Y, Farahi N, Hashjin GS. Asthma: beyond corticosteroid treatment. Arch Med Sci. 2013;9:521–6. - PMC - PubMed
    1. Mathew J, Aronow WS, Chandy D. Therapeutic options for severe asthma. Arch Med Sci. 2012;8:589–97. - PMC - PubMed
    1. Kupryś-Lipińska I, Kuna P. Omalizumab, recombinant humanized monoclonal antibody anti-IgE; new fields of studies on the therapeutic indications. Pneumonol Alergol Pol. 2009;77:43–51. - PubMed

LinkOut - more resources